ChemoCentryx Inc. (NASDAQ:CCXI) fell 3.5% on Wednesday . The company traded as low as $4.47 and last traded at $4.47, with a volume of 67,961 shares changing hands. The stock had previously closed at $4.63.

A number of brokerages recently weighed in on CCXI. Cowen and Company reaffirmed a “hold” rating on shares of ChemoCentryx in a research report on Thursday, May 19th. Zacks Investment Research downgraded shares of ChemoCentryx from a “buy” rating to a “hold” rating in a research report on Monday, May 16th.

The company has a 50-day moving average of $4.66 and a 200-day moving average of $3.75. The stock’s market capitalization is $197.98 million.

ChemoCentryx (NASDAQ:CCXI) last posted its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.27) by $0.07. On average, equities analysts forecast that ChemoCentryx Inc. will post ($0.35) earnings per share for the current year.

In related news, Director Geoffrey M. Parker purchased 40,000 shares of ChemoCentryx stock in a transaction on Friday, May 13th. The stock was purchased at an average cost of $4.03 per share, with a total value of $161,200.00. Following the acquisition, the director now directly owns 13,514 shares in the company, valued at $54,461.42. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Thomas A. Edwards purchased 50,000 shares of ChemoCentryx stock in a transaction on Tuesday, May 17th. The stock was bought at an average cost of $4.05 per share, with a total value of $202,500.00. Following the completion of the acquisition, the director now owns 91,977 shares in the company, valued at $372,506.85. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in ChemoCentryx stock. Westfield Capital Management Co. LP boosted its position in ChemoCentryx Inc. (NASDAQ:CCXI) by 1.8% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,102,332 shares of the biopharmaceutical company’s stock after buying an additional 19,375 shares during the period. Westfield Capital Management Co. LP owned 2.50% of ChemoCentryx worth $8,929,000 as of its most recent filing with the SEC.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.